Hepatología: porfirias y carcinogénesis
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (7)
2022
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
2021
-
Diagnosis and management of inborn errors of metabolism in adult patients in the emergency department
Diagnostics, Vol. 11, Núm. 11
-
High prevalence of insulin resistance in asymptomatic patients with acute intermittent porphyria and liver-targeted insulin as a novel therapeutic approach
Biomedicines, Vol. 9, Núm. 3, pp. 1-18
-
mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks
Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219
2019
-
Messenger RNA therapy for rare genetic metabolic diseases
Gut, Vol. 68, Núm. 7, pp. 1323-1330
2018
-
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909